GlassScriptPhysician profile
Diego M Diaz
NPI 1164419107
$7,452.14
in general payments reported to CMS, 2019-2025
23 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 84% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $1,655 · 2021: $613 · 2022: $1,001 · 2023: $1,116 · 2024: $1,240 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,627 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,627.37 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $2,090.11 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $1,173.93 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,142.05 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $911.64 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $605.23 | 2020-2025 | Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $286.07 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $282.86 | 2023-2025 | Bylvay |
| Janssen Scientific Affairs, LLC | $227.16 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $96.52 | 2021-2023 | |
| Alfasigma USA, INC. | $82.38 | 2020-2021 | |
| Neuraxis, INC. | $80.74 | 2024 | |
| Celltrion USA INC. | $75.02 | 2025 | Vegzelma |
| Amgen INC. | $64.87 | 2020-2023 | Amjevita, Avsola |
| Travere Therapeutics, INC. | $62.56 | 2019-2023 | Cholbam |
| Mirum Pharmaceuticals, INC. | $56.28 | 2023-2024 | Livmarli |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $53.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $46.80 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.80 | 2023 | Cyltezo |
| Mauna Kea Technologies, INC. | $24.05 | 2025 | |
| Fresenius Kabi USA, LLC | $20.96 | 2020 | |
| Aimmune Therapeutics, INC. | $20.65 | 2025 | Zenpep |
| Covidien LP | $11.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.